# US 2021/0171472 A1 · 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171472 A1
- Document ID: US20210171472A1
- Status: Published application
- Kind: A1
- Application number: 17/182,549
- Filed: 2021-02-23
- Published: 2021-06-10
- Earliest claimed: 2016-03-04
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Takahiro Katoh; Masatoshi Iida; Yuki Terauchi; Kazuya Yamaguchi; Toshiyuki Hirose; Fumiharu Yokoyama; Hikaru Nishimori; Yutaka Obuchi; Hiroshi Nabeshima; Emiri Takaki
- Web page: https://patentgrep.com/patent/US20210171472A1

## CPC

- C07D 237/04: having less than three double bonds between ring members or between ring members and non-ring members
- A61P 35/00: Antineoplastic agents
- C07D 237/02: not condensed with other rings
- C07D 237/14: Oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.

## Claims

### Claim 1

A compound of formula (1):
or a pharmaceutically acceptable salt thereof
wherein
R1 to R4 are independently hydrogen atom, halogen, OH, CN, C1-6 alkyl group, halogenated C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, or halogenated C1-6 alkoxy group, provided that one or two of R1 to R4 are hydrogen atoms, but it is not that all of three or four thereof are hydrogen atoms, and
Y is C1-6 alkylene or C2-6 alkenylene group, wherein the alkylene or alkenylene group may be substituted with one or more substituents selected independently from the group consisting of C1-6 alkyl group, halogen, and halogenated C1-6 alkyl group, further wherein a substitutable carbon atom in the substituent bonding to the alkylene or alkenylene group and another substitutable carbon atom in the alkylene or alkenylene group, or two substitutable carbon atoms in the substituent bonding to the alkylene or alkenylene group may be combined together to form a 3- to 6-membered carbon ring.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein any two of R1 to R4 are hydrogen atoms.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are independently hydrogen atom, halogen, OH, CN, C1-4 alkyl group, halogenated C1-4 alkyl group, C2-4 alkenyl group, C1-4 alkoxy group, or halogenated C1-4 alkoxy group.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are independently hydrogen atom, fluorine atom, chlorine atom, OH, CN, C1-4 alkyl group, vinyl group, or C1-4 alkoxy group.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the alkylene or alkenylene group in Y is substituted with one or more substituents selected independently from the group consisting of C1-4 alkyl group, halogen, and halogenated C1-4 alkyl group, further wherein a substitutable carbon atom in the substituent bonding to the alkylene or alkenylene group and another substitutable carbon atom in the alkylene or alkenylene group, or two substitutable carbon atoms in the substituent bonding to the alkylene or alkenylene group may be combined together to form a 3- to 6-membered carbon ring.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein a carbon atom of the alkylene or alkenylene group in Y is substituted with one or two substituents selected independently from the group consisting of C1-4 alkyl group and halogenated C1-4 alkyl group, further when the carbon atom is substituted with two substituents, each substitutable carbon atom in the two substituents may be combined together to form a 3- to 6-membered carbon ring.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the alkylene or alkenylene group in Y has no substituent.

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (1) is represented in the following formula

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compounds:
Example 1: 6-[3-bromo-5-chloro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 2: 6-[3,5-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 7: 6-[3-chloro-5-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 12: 6-[3-bromo-2-fluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 19: 6-[3-chloro-2-fluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 22: 6-[3-chloro-2-fluoro-4-(3-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 24: 6-[3-bromo-2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 26: 6-[3-bromo-5-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 31: 6-[3-chloro-4-(2-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 36: 6-[3-chloro-2-fluoro-4-(2-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 40: 6-{3-chloro-4-[(2R)-2-hydroxypropoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 44: 6-{3-chloro-4-[(1-hydroxycyclopropyl)methoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 47: 6-{3-chloro-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 48: 6-[3-bromo-2-fluoro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 53: 6-[3,5-dichloro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 54: 6-[3-chloro-2-fluoro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 55: 6-[3-chloro-4-(2-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 57: 6-[3-bromo-5-chloro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 59: 6-[2-fluoro-4-(2-hydroxypropoxy)-3-vinylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 64: 6-[3-chloro-2-fluoro-4-(2-hydroxybutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 69: 6-[3-bromo-5-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 72: 6-[3-chloro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 99: 6-[3-chloro-5-fluoro-4-(4-hydroxy-2,2-dimethylbutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 100: 6-[3,5-dichloro-4-(4-hydroxy-2,2-dimethylbutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 109: 6-[3,5-dichloro-4-(2,2-difluoro-3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 112: 6-[3-bromo-4-(2,2-difluoro-3-hydroxypropoxy)-2-fluorophenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 113: 6-[3-chloro-4-(2,2-difluoro-3-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 118: (5R)-(−)-6-[3-chloro-2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 120: (5R)-(−)-6-[4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-3-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 124: (5R)-(−)-6-[2,3-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 125: (5R)-(−)-6-[3-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 127: (5R)-(−)-6-[3-bromo-5-chloro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 131: 6-[3-chloro-2,5-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 137: 6-[3-chloro-2-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 140: 6-[3-chloro-2,5-difluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 142: 6-[3-chloro-4-(3-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 148: 6-[3-chloro-2-fluoro-4-(2-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 151: 6-{3-chloro-2-fluoro-4-[(Z)-4-hydroxy-2-butenyloxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 155: 6-(3-chloro-4-{[(1S*,2R*)-2-(hydroxymethyl)cyclopropyl]methoxy}-5-methylphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 159: 6-[3-chloro-4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 160: 6-[4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-3,5-dimethylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 167: 6-{3-chloro-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 168: 6-{3-bromo-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one,
Example 170: 6-{3,5-dichloro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, and
Example 184: 6-[2-fluoro-4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one.

### Claim 10 (depends on 1)

An agent for treating malignant tumor, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.
